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Background: The optimal medical treatment for preventing the
occurrence of contrast-induced nephropathy (CIN) in patients with
acute coronary syndromes (ACS) undergoing percutaneous coronary
intervention (PCI) is still controversial. Current preventive treatments
include saline hydration and N-acetylcysteine. It remains unclear,
conversely, the beneﬁts associated with sodium bicarbonate, whose
beneﬁt among all patients at risk for CIN have not been clearly
conﬁrmed, and fenoldopam mesylate, a dopamine A1 receptor agonist
augmenting renal plasma ﬂowwhich has reduced the risk of CIN in some
studies but not in a randomized trial. Aim of this studywas to investigate
the effects of combining high-dose fenoldopamwith sodiumbicarbonate
on the occurrence of CIN in patients with ACS.
Methods: We studied 102 patients with ACS and estimated
glomerular ﬁltration rate b 60 mL/min/1.73 m2 undergoing PCI.
Patients were randomly assigned to i.v. fenoldopam (1 mg/kg/min)
and sodium bicarbonate hydration (154 mEq/L at 3 mL/Kg for 1 h
followed by 1 mL/Kg for 6 h) (n = 51, Gr. A) or sodium bicarbonate
only (n = 51, Gr. B). All patients had low-osmolar contrast dye and
oral N-acetylcysteine (1200 mg twice daily). Creatinine levels were
assessed prior to PCI, and every 24 h for 96 h thereafter. End-points
were post-PCI creatinine levels and occurrence of CIN (as deﬁned by
an increase N 25% of the baseline creatinine) in the overall population
and in patients stratiﬁed by the Mehran risk score for CIN.
Results: Baseline creatinine was similar in the 2 groups
(1.91 + 0.51 mg/dL vs 1.95 + 0.65 mg/dL, NS). A similar volume of
dye was used in the 2 groups (155 + 75 vs 160 + 90 mL, NS).
After PCI, creatinine tended to be lower in Gr. A than in Gr. B
(1.75 + 0.52 mg/dL vs 1.99 + 0.68 mg/dL, NS), and CIN occurred in
no Gr. A patient and in 4/12 Gr. B pts. In patients with Mehran risk
score b 10, CIN occurred in Gr. B patients only. On the opposite, in
patients with Mehran score N 10, CIN occurred in both groups. Use of
fenoldopam was clinically and hemodynamically well tolerated, and
no side effects were reported by the 2 groups.
Conclusions: The combination of fenoldopam with sodium
bicarbonate has additive beneﬁcial effects over N-acetylcysteine for
the prevention of CIN in patients with ACS undergoing PCI. These




Open access under CC BY-NC-ND license.
